Skip to content Skip to footer

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…

Read more

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:  In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal valueThis report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]